Literature DB >> 10947870

Peroxisome proliferator-activated receptors in tumorigenesis: targets of tumour promotion and treatment.

S J Roberts-Thomson1.   

Abstract

The peroxisome proliferator-activated receptors (PPAR) are ligand-activated transcription factors. There are three genes that code for the PPAR isoforms: PPARalpha, PPARbeta and PPARgamma. In the present review, studies characterizing the various PPAR isoforms are discussed. Peroxisome proliferator-activated receptor alpha has been implicated in the lipid-lowering effects of the fibrate drugs. Peroxisome proliferator-activated receptor gamma has a clear role in adipocyte differentiation and is therapeutically targeted by the thiazolidinedione drugs for the treatment of type II diabetes. The physiological role of PPARbeta is less well understood but, as described in the present review, recent studies have implicated it with a role in colon cancer. In the present review, particular attention is focused on the role of PPAR in the regulation of expression of proteins associated with cell cycle control and tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10947870     DOI: 10.1046/j.1440-1711.2000.00921.x

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  25 in total

1.  Lipid profiles and the risk of endometrial cancer in the Swedish AMORIS study.

Authors:  Divya Seth; Hans Garmo; Annette Wigertz; Lars Holmberg; Niklas Hammar; Ingmar Jungner; Mats Lambe; Göran Walldius; Mieke Van Hemelrijck
Journal:  Int J Mol Epidemiol Genet       Date:  2012-05-15

2.  Expression of peroxisome proliferator-activated receptors in zebrafish (Danio rerio) depending on gender and developmental stage.

Authors:  Arantza Ibabe; Eider Bilbao; Miren P Cajaraville
Journal:  Histochem Cell Biol       Date:  2004-12-23       Impact factor: 4.304

3.  Ligands for PPARgamma and RAR cause induction of growth inhibition and apoptosis in human glioblastomas.

Authors:  Chuanbing Zang; Marlies Wächter; Hongyu Liu; Maximilian G Posch; Martin H Fenner; Christine Stadelmann; Andreas von Deimling; Kurt Possinger; Keith L Black; H Phillip Koeffler; Elena Elstner
Journal:  J Neurooncol       Date:  2003-11       Impact factor: 4.130

4.  Antidiabetic thiazolidinediones induce ductal differentiation but not apoptosis in pancreatic cancer cells.

Authors:  Elisabetta Ceni; Tommaso Mello; Mirko Tarocchi; David-W Crabb; Anna Caldini; Pietro Invernizzi; Calogero Surrenti; Stefano Milani; Andrea Galli
Journal:  World J Gastroenterol       Date:  2005-02-28       Impact factor: 5.742

5.  The impact of BMI on subgroups of uterine cancer.

Authors:  K Lindemann; L J Vatten; M Ellstrøm-Engh; A Eskild
Journal:  Br J Cancer       Date:  2009-06-30       Impact factor: 7.640

6.  Chemopreventive efficacies of rosiglitazone, fenretinide and their combination against rat mammary carcinogenesis.

Authors:  Hilal Kocdor; Mehmet Ali Kocdor; Tulay Canda; Duygu Gurel; Ruksan Cehreli; Osman Yilmaz; Mehmet Alakavuklar; Gul Guner
Journal:  Clin Transl Oncol       Date:  2009-04       Impact factor: 3.405

7.  Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARgamma independent mechanisms.

Authors:  A Galli; E Ceni; D W Crabb; T Mello; R Salzano; C Grappone; S Milani; E Surrenti; C Surrenti; A Casini
Journal:  Gut       Date:  2004-11       Impact factor: 23.059

8.  Novel herbal flavonoids promote apoptosis but differentially induce cell cycle arrest in human colon cancer cell.

Authors:  Kathy Ka-Wai Auyeung; Joshua Ka-Shun Ko
Journal:  Invest New Drugs       Date:  2009-01-13       Impact factor: 3.850

9.  Combined low doses of PPARgamma and RXR ligands trigger an intrinsic apoptotic pathway in human breast cancer cells.

Authors:  Daniela Bonofiglio; Erika Cione; Hongyan Qi; Attilio Pingitore; Mariarita Perri; Stefania Catalano; Donatella Vizza; Maria Luisa Panno; Giuseppe Genchi; Suzanne A W Fuqua; Sebastiano Andò
Journal:  Am J Pathol       Date:  2009-07-30       Impact factor: 4.307

10.  The Role of PPARgamma Receptors and Leukotriene B(4) Receptors in Mediating the Effects of LY293111 in Pancreatic Cancer.

Authors:  Thomas E Adrian; Rene Hennig; Helmut Friess; Xianzhong Ding
Journal:  PPAR Res       Date:  2009-01-27       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.